RenovoRxRNXT
RNXT
About: RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Employees: 10
0
Funds holding %
of 7,324 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
663% more capital invested
Capital invested by funds: $1.31M [Q4 2024] → $9.98M (+$8.67M) [Q1 2025]
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
50% more funds holding
Funds holding: 18 [Q4 2024] → 27 (+9) [Q1 2025]
24.14% more ownership
Funds ownership: 4.22% [Q4 2024] → 28.36% (+24.14%) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
144%
upside
Avg. target
$7.25
489%
upside
High target
$11.50
835%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo | 835%upside $11.50 | Buy Maintained | 5 Jun 2025 |
HC Wainwright & Co. Swayampakula Ramakanth | 144%upside $3 | Buy Reiterated | 19 May 2025 |
Financial journalist opinion
Neutral
Business Wire
3 days ago
RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, today announced the launch of the PanTheR Post-Marketing Registry Study (NCT06805461). The initiation of this study demonstrates RenovoRx's commitment to innovation and RenovoCath's current and future potential. The study will serve as a critical.
Neutral
Business Wire
2 weeks ago
RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced it will host its second quarter 2025 financial results and business highlights conference call on August 14, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at h.
Neutral
Seeking Alpha
2 months ago
RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript
RenovoRx, Inc. (NASDAQ:RNXT ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Valter Pinto - IR Ramtin Agah - Founder and Chief Medical Officer Shaun Bagai - CEO Ronald Kocak - VP Controller and Principal Accounting Officer Conference Call Participants Rafay Khalid - Ascendiant Capital Markets Operator Good afternoon, everyone, and welcome to the RenovoRx Q1 2025 Financial and Operational Highlights Conference Call. All participants will be in a listen-only mode.
Neutral
Zacks Investment Research
2 months ago
RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.
Neutral
Business Wire
2 months ago
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced its financial results and business updates for the first quarter ended March 31, 2025. RenovoCath powers RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform. “I am pleased to report a milestone event for Reno.
Neutral
Business Wire
2 months ago
RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath©, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer, Shaun Bagai, will participate in a fireside chat at the Alliance Global Partners (A.G.P.) Virtual Healthcare Company Showcase hosted by Scott Henry, Managing Director and Healthcare Analyst at A.G.P., o.
Neutral
Business Wire
2 months ago
U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent NO. 12,290,564, becomes effective today, May 6, 2025. This patent, titled “Methods for Treating Tumors,” expand.
Neutral
Business Wire
2 months ago
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced it will host its first quarter 2025 financial results conference call on May 15th, 2025, at 4:30 p.m. ET. Additional details will be available in the Investor Relations section of the Company's website at https://ir.renovorx.com/. Ev.
Neutral
Business Wire
3 months ago
Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Johns Hopkins Medicine is now initiated to enroll patients with locally advanced pancreatic cancer (LAPC) in RenovoRx's ongoing Phase III TIGeR-PaC clinical trial. Johns Hopkins Medicine becomes the newest addition to a disting.
Neutral
Business Wire
3 months ago
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced that it is increasing production of its FDA-cleared RenovoCath catheter-based device in order to meet increased demand for the targeted delivery of diagnostic and/or therapeutic agents from oncologists and interventional radiologists.
Charts implemented using Lightweight Charts™